Novo Nordisk's John Kuckelman Talks Eli Lilly Obesity Drug Ads

episode

Bloomberg Talks not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Bloomberg Talks

US Representative Nicole Malliotakis (R-NY) Talks Ceasefire Talks, Reconciliation Push 12 min · 10 Apr 2026

CoreWeave CEO Michael Intrator Talks Anthropic Deal 9 min · 10 Apr 2026

World Bank President Talks Strait of Hormuz 11 min · 09 Apr 2026

McCormick CEO Brendan Foley Talks Unilever Deal 9 min · 09 Apr 2026

Claudia Sahm Talks Inflation Duration, Investment and Consumer Spending 7 min · 09 Apr 2026

EU's Top Data Regulator Talks Tech Rules 8 min · 09 Apr 2026

All episodes from Bloomberg Talks →

Report any issue

Source

Recorded21 Jul 2026

Publisheromnycontent.com ↗

Handlerec:19378998

Show notes

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in